CDH1 and cancer: Benign and malignant tumours diverged significantly with respect to both P- and E-cadherin immunoexpression, with most of the malignant tumours (80%) overexpressing P-cadherin and the vast majority of the benign tumours (90%) preserving the expression of E-cadherin (Table 1).